Ekins, S., N. K. Litterman, R. J. G. Arnold, R. W. Burgess, J. S. Freundlich, S. J. Gray, J. J. Higgins, B. Langley, D. E. Willis, L. Notterpek, D. Pleasure, M. W. Sereda and A. Moore: A brief review of recent Charcot-Marie-Tooth research and priorities. In: F1000research 4, Seq. No.: 53 (2015).
Chumakov, I., A. Milet, N. Cholet, G. Primas, A. Boucard, Y. Pereira, E. Graudens, J. Mandel, J. Laffaire, J. Foucquier, F. Glibert, V. Bertrand, K.-A. Nave, M. W. Sereda, E. Vial, M. Guedj, R. Hajj, S. Nabirotchkin and D. Cohen: Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. In: Orphanet Journal of Rare Diseases 9, 1, Seq. No.: 201 (2014).
Fledrich, R., R. M. Stassart, A. Klink, L. M. Rasch, T. Prukop, L. Haag, D. Czesnik, T. Kungl, T. A. M. Abdelaal, N. Keric, C. Stadelmann, W. Brück, K.-A. Nave and M. W. Sereda: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. In: Nature Medicine 20, 9, 1055-1061 (2014).
Prukop, T., D. B. Epplen, T. Nientiedt, S. P. Wichert, R. Fledrich, R. M. Stassart, M. J. Rossner, J. M. Edgar, H. B. Werner, K.-A. Nave and M. W. Sereda: Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. In: American Journal of Human Genetics 94, 533-546 (2014).
Tönges, L., R. Günther, M. Suhr, J. Jansen, A. Balck, K.-A. Saal, E. Barski, T. Nientied, A. A. Götz, J.-C. Koch, B. K. Mueller, J. H. Weishaupt, M. W. Sereda, U.-K. Hanisch, M. Bähr and P. Lingor: Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. In: GLIA 62, 2, 217-232 (2014).
Mannil, M., A. Solari, A. Leha, A. L. Pelayo-Negro, J. Berciano, B. Schlotter-Weigel, M. C. Walter, B. Rautenstrauss, T. J. Schnizer, A. Schenone, P. Seeman, C. Kadian, O. Schreiber, N. G. Angarita, G. M. Fabrizi, F. Gemignani, L. Padua, L. Santoro, A. Quattrone, G. Vita, D. Calabrese, CMT-TRIAAL/CMT-TRAUK Group, P. Young, M. Laurà, J. Haberlová, R. Mazanec, W. Paulus, T. Beissbarth, M. E. Shy, M. M. Reilly, D. Pareyson and M. W. Sereda: Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. In: Neuromuscular Disorders 24, 1003-1017 (2014).
Stassart, R. M., R. Fledrich, V. Velanac, B. G. Brinkmann, M. H. Schwab, D. Meijer, M. W. Sereda and K.-A. Nave: A role for Schwann cell-derived neuregulin-1 in remyelination. In: Nature Neuroscience 16, 1, 48-54 (2013).
Schwab, M. H., M. W. Sereda and K.-A. Nave: Neuron-glial interactions: Schwann cells. In: Patterning and cell type specification developing CNS and PNS: Comprehensive developmental neuroscience. (Eds.) Rubenstein, John L.; Rakic, Pasko. Elsevier, Amsterdam [et al.] (2013) 851-869.
Goebbels, S., J. H. Oltrogge, S. Wolfer, G. L. Wieser, T. Nientiedt, A. Pieper, T. Ruhwedel, M. Groszer, M. W. Sereda and K.-A. Nave: Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy. In: EMBO Molecular Medicine 4, 6, 486-499 (2012).
Fledrich, R., R. M. Stassart and M. W. Sereda: Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. In: British Medical Bulletin 102, 89-113 (2012).
The Max Planck Society does not take any responsibility for the content of this export.